Similar articles for PMID: 21529987

Year	Number of Results
1994	1
2002	1
2004	6
2005	8
2006	10
2007	9
2008	16
2009	14
2010	15
2011	25
2012	29
2013	22
2014	10
2015	7
2016	7
2017	3
2018	5
2019	3
2020	4
2021	2
2022	1
2024	0

1

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

Hata A, Katakami N, Yoshioka H, Fujita S, Kunimasa K, Nanjo S, Otsuka K, Kaji R, Tomii K, Iwasaku M, Nishiyama A, Hayashi H, Morita S, Ishida T. Hata A, et al. Lung Cancer. 2011 Nov;74(2):268-73. doi: 10.1016/j.lungcan.2011.03.010. Epub 2011 May 6. Lung Cancer. 2011. PMID: 21529987

2

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.

Kaira K, Naito T, Takahashi T, Ayabe E, Shimoyama R, Kaira R, Ono A, Igawa S, Shukuya T, Murakami H, Tsuya A, Nakamura Y, Endo M, Yamamoto N. Kaira K, et al. Lung Cancer. 2010 Apr;68(1):99-104. doi: 10.1016/j.lungcan.2009.05.006. Epub 2009 Jun 21. Lung Cancer. 2010. PMID: 19540616

3

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.

Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ. Kim ST, et al. Cancer. 2010 Jun 15;116(12):3025-33. doi: 10.1002/cncr.25130. Cancer. 2010. PMID: 20564408 Free article.

4

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.

Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M. Dudek AZ, et al. Lung Cancer. 2006 Jan;51(1):89-96. doi: 10.1016/j.lungcan.2005.09.002. Epub 2005 Nov 14. Lung Cancer. 2006. PMID: 16290256

5

Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.

Han JY, Kim JY, Lee SH, Yoo NJ, Choi BG. Han JY, et al. Lung Cancer. 2011 Nov;74(2):293-9. doi: 10.1016/j.lungcan.2011.02.021. Epub 2011 Mar 26. Lung Cancer. 2011. PMID: 21440951 Clinical Trial.

6

Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.

Song ZB, Yu YF, Chen ZW, Lu S. Song ZB, et al. Chin Med J (Engl). 2011 Aug;124(15):2279-83. Chin Med J (Engl). 2011. PMID: 21933557

7

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

Horiike A, Yamamoto N, Tanaka H, Yanagitani N, Kudo K, Ohyanagi F, Ono A, Naito T, Murakami H, Horai T, Nishio M. Horiike A, et al. Anticancer Res. 2014 Apr;34(4):1975-81. Anticancer Res. 2014. PMID: 24692734 Clinical Trial.

8

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.

Wu JY, Wu SG, Yang CH, Chang YL, Chang YC, Hsu YC, Shih JY, Yang PC. Wu JY, et al. Lung Cancer. 2011 May;72(2):205-12. doi: 10.1016/j.lungcan.2010.08.013. Epub 2010 Sep 15. Lung Cancer. 2011. PMID: 20832137

9

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.

Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD. Spigel DR, et al. J Clin Oncol. 2011 Jun 20;29(18):2582-9. doi: 10.1200/JCO.2010.30.7678. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576636 Clinical Trial.

10

Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.

Koyama N, Uchida Y. Koyama N, et al. Anticancer Res. 2013 Nov;33(11):5083-9. Anticancer Res. 2013. PMID: 24222153

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

165 results

Results by year